Sanjivani Paranteral Quarterly Results for Trading Insights
In Mar 2026, Sanjivani Paranteral (SANJIVIN) reported revenue ₹14 Cr and net profit ₹1 Cr — revenue -26.3% YoY. Also explore Sanjivani Paranteral stock price data download to track price trends across different timeframes.
SANJIVIN Quarterly Results — Revenue, Profit & EPS Highlights
Sanjivani Paranteral latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Browse SANJIVIN cash flow statement for revenue, profit, balance sheet and cash flow data.
- Revenue of ₹14 Cr in Mar 2026 (-12.5% vs Sept 2025, -26.3% vs Mar 2025)
- Net Profit of ₹1 Cr in Mar 2026 (-50.0% vs Sept 2025, -50.0% vs Mar 2025)
- EBITDA of ₹2 Cr in Mar 2026 (+0.0% vs Sept 2025)
- Operating Margin of 12.0% in Mar 2026 (-3.0pp vs Sept 2025)
- Earnings Per Share of ₹0.49 in Mar 2026 (-63.2% vs Sept 2025)
Sanjivani Paranteral Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SANJIVIN quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 14 | 16 | 19 | 18 | 22 | -12.5% | -26.3% |
| Net Profit (₹ Cr) | 1 | 2 | 2 | 2 | 3 | - | - |
| EBITDA (₹ Cr) | 2 | 2 | 3 | 3 | 4 | - | - |
| EPS (₹) | 0.49 | 1.33 | 1.84 | 1.46 | 2.21 | - | - |
| Operating Margin (%) | 12.0% | 15.0% | 14.0% | 15.0% | 17.0% | - | - |
SANJIVIN Share Price Trend — 1-Year Movement Across Quarterly Results
Sanjivani Paranteral 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit SANJIVIN screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SANJIVIN vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Sanjivani Paranteral latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹457,721.13 Cr | 1912.8 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 169.3 |
|
Divis Laboratories
Mar 2026 |
₹174,081.02 Cr | 6857.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 242.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹161,380.94 Cr | 4822.7 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 419.0 |
|
Cipla
Mar 2026 |
₹117,800.00 Cr | 1472.3 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 214.3 |
|
Zydus Life Science
Mar 2026 |
₹115,505.60 Cr | 1147.9 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 90.7 |
All amounts in ₹ Crores